Zepteon
About Zepteon
Zepteon is a privately held corporation that develops purification tools capable of separating antibodies with specific sugar structures, which are more potent against diseases like cancer. The corporation’s chromatography resins are being used to prepare material to evaluate the effects of a wide range of nonfucosylation levels in studies of antibody function. Its technology is also being used analytically, to determine antibody nonfucosylation levels as a function of cell culture conditions. Zepteon’s technology has the ability to support the preparation of a biosimilar antibody filing, increasing the chances of regulatory success and increasing speed to market. Zepteon was founded in 2012 by [Austin W. Boesch](https://www.crunchbase.com/person/austin-w--boesch) and [Glen R. Bolton](https://www.crunchbase.com/person/dr-glen-r--bolton#/entity). It is based in Boston, M.A.
Company Metrics
- Employees: 1-10
- Monthly Visits: None
- Tech Stack: 3 active products
Financial Information
- Estimated Revenue: $10M to $50M
- Total Funding: 210000 USD
- Last Funding: 210000 USD (Seed)
- Funding Status: Seed
Technology Stack
Zepteon actively uses 3 products in their tech stack.
Market Presence
Industries: Biotechnology, Health Care, Wellness
Headquarters: Boston, Massachusetts, United States